CSIMarket Company Name, Ticker, Competitors, else..
 


In Vitro & In Vivo Diagnostic Substances Industry Profitability

Profitability Information & Trends 
  
Category:   Period:  

In Vitro & In Vivo Diagnostic Substances Industry Profitability Ratios 3 Q 2022 2 Q 2022 1 Q 2022 4 Q 2021 3 Q 2021
  2022 2022 2022 2021 2021
Gross Margin 43.71 % 53.8 % 72.08 % 100 % 100 %
Gross Margin Annual (TTM) 42.91 % 67.87 % 70.38 % - -
Gross Margin Ranking # 60 # 37 # 17 # 33 # 24
EBITDA Margin 4.22 % 14.27 % 58.95 % - -
EBITDA Margin Annual (TTM) - 46.89 % 52.6 % - -
EBITDA Margin Ranking # 96 # 73 # 3 # 36 # 12
Operating Margin - 10.94 % 57.09 % - -
Operating Margin Annual (TTM) - 44.39 % 49.9 % - -
Operating Margin Ranking # 101 # 85 # 2 # 37 # 13
Pre-Tax Margin - 5.44 % 57.06 % - -
Pre-Tax Margin Annual (TTM) - 43.04 % 49.68 % - -
Pre-Tax Margin Ranking # 101 # 89 # 1 # 29 # 10
Net Margin - 2.07 % 44.04 % - -
Net Margin Annual (TTM) - 32.72 % 38.43 % - -
Net Margin Ranking # 97 # 95 # 1 # 31 # 10

New: More In Vitro & In Vivo Diagnostic Substances Industry historic profitability ratios >>

Comment on the 3 Q 2022 Gross Margin within the In Vitro & In Vivo Diagnostic Substances Industry

In Vitro & In Vivo Diagnostic Substances Industry increased Gross Margin through reduction in Cost of Sales and despite contraction in Gross Profit by -1.65 % and Revenue -4.92 %. Gross Margin in 3 Q 2022 was 43.71 %, below Industry average.

On the trailing twelve months basis gross margin in 3 Q 2022 fell to 42.91 %.

Within Healthcare sector 4 other industries have achieved higher gross margin. Gross margin total ranking has deteriorated compare to previous quarter from 37 to 60.

Note, Numbers include only companies who have reported earnings results. Numbers change as more businesses report financial results. See the full List.

Gross Margin Statistics
High Average Low
141.22 % 82.17 % 43.71 %
4. quarter 2020   3. quarter 2022

Gross Margin Industry Ranking
Within: No.
Healthcare Sector # 5
Overall # 60


Other Gross Margins
Compare Industry's gross margin to Mchp's or S&P Gross profits within In Vitro & In Vivo Diagnostic Substances Industry
Highest Ranking Gross Margins Lowest Ranking Gross Margins
Profitability for Mchp's Suppliers Definiton of Gross Margin

In Vitro & In Vivo Diagnostic Substances Industry EBITDA Margin Statistics
 
EBITDA Margin Statistics
High Average Low
103.7 % -1160.97 % -7174.09 %
4. quarter 2020   4. quarter 2021

EBITDA Margin Industry Ranking
Within: No.
Healthcare Sector # 6
Overall # 96

EBITDA Margin Comment on the 3 Q 2022 within the In Vitro & In Vivo Diagnostic Substances Industry

In Vitro & In Vivo Diagnostic Substances Industry's Revenue increased sequentially by -4.92 % faster than Ebitda increase of -204.42 %, this led to contraction in Ebitda Margin to 4.22 %, higher than Industry average.



Within Healthcare sector 5 other industries have achieved higher ebitda margin. Ebitda margin total ranking has deteriorated compare to previous quarter from 73 to 96.

Other EBITDA Margins
Compare Industry's EBITDA margin to Mchp's or S&P Gross profits within In Vitro & In Vivo Diagnostic Substances Industry
Highest Ranking EBITDA Margins Lowest Ranking EBITDA Margins
Profitability for Industry's Suppliers Industry Net Cash Flow Margin


In Vitro & In Vivo Diagnostic Substances Industry Operating Margin Statistics
 

Operating Margin Comment on the 3 Q 2022 within the In Vitro & In Vivo Diagnostic Substances Industry

In Vitro & In Vivo Diagnostic Substances Industry Operating Loss decreased compare to previous quarter.



Within Healthcare sector 5 other industries have achieved higher operating margin. Operating margin total ranking has deteriorated compare to previous quarter from 85 to 101.



Operating Margin Statistics
High Average Low
57.09 % -1186.21 % -7228.19 %
1. quarter 2022   4. quarter 2021

Operating Margin Industry Ranking
Within: No.
Healthcare Sector # 6
Overall # 101

In Vitro & In Vivo Diagnostic Substances Industry Pre-Tax Margin Statistics
 


Pre-Tax Margin Statistics
High Average Low
87.19 % -1177.88 % -7253.84 %
4. quarter 2020   4. quarter 2021

Comment on the 3 Q 2022 Pre-Tax Margin in the In Vitro & In Vivo Diagnostic Substances Industry

In Vitro & In Vivo Diagnostic Substances Industry Pre-Tax Loss decreased compare to previous quarter.



Within Healthcare sector 5 other industries have achieved higher Pre-Tax Margin. Pre-Tax Margin total ranking has deteriorated compare to previous quarter from 89 to 101.
Pre-Tax Margin Industry Ranking
Within: No.
Healthcare Sector # 6
Overall # 101

Pre-Tax Margins
Compare Industry's pre-tax margin to Mchp's or S&P Net profits within In Vitro & In Vivo Diagnostic Substances Industry
Highest Ranking Net Margins Lowest Ranking Net Margins
Profitability for Mchp's Competitors Industry Tax Rate


In Vitro & In Vivo Diagnostic Substances Industry Net Margin Statistics
 





Net Margin Comment on the 3 Q 2022 in the In Vitro & In Vivo Diagnostic Substances Industry

In Vitro & In Vivo Diagnostic Substances Industry Net Loss decreased compare to previous quarter.



Within Healthcare sector 5 other industries have achieved higher Net margin. Net margin total ranking has deteriorated compare to previous quarter from 95 to 97.

Net Margin Statistics
High Average Low
61.99 % -1185.14 % -7253.84 %
4. quarter 2020   4. quarter 2021
Net Margin Industry Ranking
Within: No.
Healthcare Sector # 6
Overall # 97

Other Net Margins
Compare Industry's net margin to Mchp's or S&P Net profits within In Vitro & In Vivo Diagnostic Substances Industry
Highest Ranking Net Margins Lowest Ranking Net Margins
Profitability for Mchp's Suppliers Definiton of Net Margin





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071